Paradigm Biopharmaceuticals (CHIA:PAR) - Stock Price, News & Analysis

PAR Stock Overview

Engages in the research and development of therapeutic products for human use in Australia. More details

PAR fundamental analysis
Snowflake Score
Valuation	1/6
Future Growth	0/6
Past Performance	0/6
Financial Health	4/6
Dividends	0/6

Risk Analysis

Has less than 1 year of cash runway

Makes less than USD$1m in revenue (A$0)

Currently unprofitable and not forecast to become profitable over the next 3 years

Does not have a meaningful market cap (A$95M)

+ 2 more risks

Paradigm Biopharmaceuticals Limited Competitors

Cynata Therapeutics

ASX:CYP

AU$38.8m

Beroni Group

NSX:BTG

AU$75.9m

Noxopharm

ASX:NOX

AU$29.2m

Dimerix

ASX:DXB

AU$181.1m

Price History & Performance

Summary of all time highs, changes and price drops for Paradigm Biopharmaceuticals
Historical stock prices
Current Share Price	AU$0.28
52 Week High	AU$0.47
52 Week Low	AU$0.17
Beta	0.87
11 Month Change	27.91%
3 Month Change	17.02%
1 Year Change	-31.25%
33 Year Change	-87.78%
5 Year Change	-93.04%
Change since IPO	-22.54%

Recent updates

Shareholder Returns

	PAR	AU Biotechs	AU Market
7D	10.0%	-3.6%	1.5%
1Y	-31.3%	10.0%	17.2%

Return vs Industry: PAR underperformed the Australian Biotechs industry which returned 10% over the past year.

Return vs Market: PAR underperformed the Australian Market which returned 17.2% over the past year.

Price Volatility

Is PAR's price volatile compared to industry and market?
PAR volatility
PAR Average Weekly Movement	14.3%
Biotechs Industry Average Movement	9.7%
Market Average Movement	8.6%
10% most volatile stocks in AU Market	17.3%
10% least volatile stocks in AU Market	3.4%

Stable Share Price: PAR's share price has been volatile over the past 3 months compared to the Australian market.

Volatility Over Time: PAR's weekly volatility (14%) has been stable over the past year, but is still higher than 75% of Australian stocks.

About the Company

Founded	Employees	CEO	Website
2014	n/a	Paul Rennie	www.paradigmbiopharma.com

Paradigm Biopharmaceuticals Limited engages in the research and development of therapeutic products for human use in Australia. It lead candidate is Zilosul, an injectable pentosan polysulfate sodium drugs for the treatment of osteoarthritis, mucopolysaccharidosis, ross river virus, chikungunya virus, chronic heart failure, allergic respiratory, and acute respiratory distress syndrome diseases. The company was incorporated in 2014 and is headquartered in Melbourne, Australia.

Paradigm Biopharmaceuticals Limited Fundamentals Summary

How do Paradigm Biopharmaceuticals's earnings and revenue compare to its market cap?
PAR fundamental statistics
Market cap	AU$94.60m
Earnings (TTM)	-AU$58.65m
Revenue (TTM)	n/a

0.0x

P/S Ratio

-1.6x

P/E Ratio

Is PAR overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
PAR income statement (TTM)
Revenue	AU$0
Cost of Revenue	AU$8.99k
Gross Profit	-AU$8.99k
Other Expenses	AU$58.64m
Earnings	-AU$58.65m

Last Reported Earnings

Jun 30, 2024

Next Earnings Date

n/a

Earnings per share (EPS)	-0.17
Gross Margin	0.00%
Net Profit Margin	0.00%
Debt/Equity Ratio	0%

How did PAR perform over the long term?

See historical performance and comparison

PAR Stock Overview

Risk Analysis

Paradigm Biopharmaceuticals Limited Competitors

ASX:CYP

AU$38.8m

NSX:BTG

AU$75.9m

ASX:NOX

AU$29.2m

ASX:DXB

AU$181.1m

Price History & Performance

Recent News & Updates

Donna Skerrett Steps Down from Position as an Executive Director on the Board of Paradigm Biopharmaceuticals Ltd

Paradigm Biopharmaceuticals Ltd Plans to Submit the Finalized Protocol for Its Phase 3 Clinical Trial

Non-Executive Director recently bought AU$73k worth of stock

Paradigm Biopharmaceuticals Limited, Annual General Meeting, Nov 19, 2024

New major risk - Financial position

New minor risk - Profitability

Recent updates

Donna Skerrett Steps Down from Position as an Executive Director on the Board of Paradigm Biopharmaceuticals Ltd

Paradigm Biopharmaceuticals Ltd Plans to Submit the Finalized Protocol for Its Phase 3 Clinical Trial

Non-Executive Director recently bought AU$73k worth of stock

Paradigm Biopharmaceuticals Limited, Annual General Meeting, Nov 19, 2024

New major risk - Financial position

New minor risk - Profitability

Insufficient new directors

New major risk - Financial position

New minor risk - Share price stability

New minor risk - Shareholder dilution

New minor risk - Share price stability

Paradigm Biopharmaceuticals Ltd Announces Resignation of John Gaffney as Independent Non Executive Director, Effective Immediately

Forecast breakeven date pushed back to 2025

Paradigm Biopharmaceuticals Limited, Annual General Meeting, Nov 29, 2023

Full year 2023 earnings released: AU$0.21 loss per share (vs AU$0.17 loss in FY 2022)

Founder recently bought AU$76k worth of stock

Paradigm Biopharmaceuticals Ltd Advises the First Safety Review Meeting of the Data Monitoring Committee (DMC) for the Pivotal Para_OA_002 Clinical Trial

Founder recently bought AU$62k worth of stock

Paradigm Biopharmaceuticals Limited Announces Executive Changes

Paradigm Biopharmaceuticals Limited Announces an Abstract on Paradigm's Phase 2 Clinical Trial Evaluating Injectable Pentosan Polysulfate Sodium

Paradigm Biopharmaceuticals Limited Announces First UK Subject Randomised and Dosed for the Pivotal Phase 3 Trial for the Treatment of Pain Associated with Knee OA

Paradigm Biopharmaceuticals Ltd Announces Successful Primary Endpoint in Phase 2 Trial

Paradigm Biopharmaceuticals Ltd Provides an Update on the Ongoing Multi-Centre Double-Blind Randomised Phase 2 Study Comparing PPS to Placebo in Mucopolysaccharidosis Type VI (MPS-VI) Patients

Paradigm Biopharmaceuticals Limited, Annual General Meeting, Nov 18, 2022

Paradigm Biopharmaceuticals Limited Appoints Abby Macnish as Interim Company Secretary

Paradigm Biopharmaceuticals Ltd Announces MPS Clinical Program Update and Paradigm to Present At the International Conference on Lysosomal Diseases

Paradigm Biopharmaceuticals Limited Reports Important Global Progress for the Para_Oa_002 Phase 3 Clinical Trial Evaluating Zilosul® for Osteoarthritis

Paradigm Biopharmaceuticals Limited Announces PARA_OA_008 Study Evaluating Zilosul® Mechanism and Disease Modifying Effects Completes Recruitment

Forecast to breakeven in 2024

Paradigm Biopharmaceuticals Limited Announces Chief Executive Officer Changes

Paradigm Biopharmaceuticals Limited Doses First US Subjects Under Phase 3 Trial

U.S. Food and Drug Administration Grants Fast Track Designation for Paradigm Biopharmaceuticals Ltd of Phase 3 Program

Founder & Non-Executive Chairman recently bought AU$51k worth of stock

No longer forecast to breakeven

Paradigm Biopharmaceuticals Limited Announces First Subjects Randomised and Dosed in Para_0A_002 Phase 3 Study in Australia

Paradigm Biopharmaceuticals Ltd Reports Postive Topline Results in Heart Failure Model

Paradigm Biopharmaceuticals Limited Reports Preliminary Results from Phase 2 Mps I Study

Paradigm Biopharmaceuticals Limited Announces First MPS-VI Patient Dosed Under Phase 2 Trial in Brazil Investigating PPS for the Treatment of MPS-VI

Paradigm Biopharmaceuticals Limited Receives Feedback from US FDA on IND Submission

Paradigm Biopharmaceuticals Limited Announces Australian Ethics Approval for Paradigm's ARA_OA_002 Pivotal Phase 3 Clinical Trial in Participants with Knee OA

Forecast to breakeven in 2024

Paradigm Biopharmaceuticals Limited Makes Progress with Investigational New Drug Application

Paradigm Biopharmaceuticals Limited Receives Key Regulatory Approvals for MPS VI Study

Paradigm Biopharmaceuticals Ltd Receives First Revenue Through Physician Prescription of Zilosul to Patients Via the TGA SAS

Paradigm Biopharmaceuticals Ltd Provides an Update on its IND Application to the Us Food and Drug Administration

Paradigm Biopharmaceuticals Limited Updates Phase 2A, Randomised, Double-Blind, Placebo- Controlled Study

New 90-day low: AU$2.30

Paradigm Biopharmaceuticals Ltd Announces It Has Received Ethics Approval for Its Phase 2 Clinical Trial to Evaluate the Treatment Effects of Pentosan Polysulfate Sodium

Paradigm Biopharmaceuticals Limited Appoints Helen Fisher as Non-Executive Director and Chair of the Audit and Risk Committee

Paradigm Biopharmaceuticals Ltd Reports Ongoing Data Update on Patients Who Received Zilosul Under the Therapeutic Goods Administration (TGA) Special Access Scheme

New 90-day low: AU$2.38

New 90-day low: AU$2.42

Paradigm Biopharmaceuticals Ltd Receives the Written Response from the Type-C meeting with the US Food and Drug Administration (FDA) regarding Zilosul® for the Treatment of Osteoarthritis

Paradigm Biopharmaceuticals Limited Announces Resignation of Chris Fullerton as Non- Executive Director

Paradigm Biopharmaceuticals Limited Announces First Patient Dosed in Phase 2 Clinical Trial Evaluating PPS in Mucopulysaccharidoses Type-1

Paradigm Biopharmaceuticals Limited Adds Senior Executives to its Team

Paradigm Biopharmaceuticals Ltd Clear Path Towards Zilosul's Oa Phase 3 Clinical Trial and Product Registration in Europe

Paradigm Biopharmaceuticals Ltd Reports Additional Data on Patients Who Received Zilosul® Under the Therapeutic Goods Administration (TGA) Special Access Scheme (SAS)

New 90-day low: AU$2.32

New 90-day low - AU$2.54